Astera Labs reported capital expenditure of $38M for fiscal 2025, +9.6% versus $34M in fiscal 2024.
Capex equals 4% of fiscal-year revenue ($853M).
The highest single reported period was $8M (period ending 2026-03-31).
The latest reported period, 6 months to 2026-06-30, shows $28M; the dataset covers 15 reported periods (2022–2026), all from SEC XBRL filings.
Every capital-expenditure figure Astera Labs has reported to the SEC, unedited. Capex is the XBRL concept PaymentsToAcquirePropertyPlantAndEquipment; a capex/revenue ratio above 100% means the company is investing more than it earns to secure capacity. Each row links to the filing it came from.
| Fiscal year | Capex | YoY |
|---|---|---|
| FY2025 | $38M | +10% |
| FY2024 | $34M | +1140% |
| FY2023 | $3M | -29% |
| FY2022 | $4M | — |
| Period end | Period | Capex |
|---|---|---|
| 2026-06-30 | FY2026 6 mo. cumulative | $28M |
| 2026-03-31 | FY2026 Q1 | $8M |
| 2025-12-31 | FY2025 FY | $38M |
| 2025-09-30 | FY2025 9 mo. cumulative | $19M |
| 2025-06-30 | FY2025 6 mo. cumulative | $7M |
| 2025-03-31 | FY2025 Q1 | $5M |
| 2024-12-31 | FY2024 FY | $34M |
| 2024-09-30 | FY2024 9 mo. cumulative | $19M |
| 2024-06-30 | FY2024 6 mo. cumulative | $2M |
| 2024-03-31 | FY2024 Q1 | $3M |
| 2023-12-31 | FY2023 FY | $3M |
| 2023-09-30 | FY2023 9 mo. cumulative | $2M |
| 2023-06-30 | FY2023 6 mo. cumulative | $1M |
| 2023-03-31 | FY2023 Q1 | $439K |
| 2022-12-31 | FY2022 FY | $4M |
Source: SEC XBRL company-concept API, concept PaymentsToAcquirePropertyPlantAndEquipment, CIK 1736297. See Methodology.